Meyers, Rachel

Safety and efficacy of RNAi therapy for transthyretin amyloidosis

Coelho, T., Adams, D., Silva, A., Lozeron, P., Hawkins, P. N., Mant, T., Perez, J., Chiesa, J., Warrington, S., Tranter, E., et al. (2013) · New England Journal of Medicine

Amyloidosis: Diagnosis, Treatment, OutcomesRNA Interference and Gene Delivery

Cited by 971

5′-triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma

Poeck, H., Besch, R., Maihoefer, C., Renn, M., Tormo, D., Morskaya, S. S., Kirschnek, S., Gaffal, E., Landsberg, J., Hellmuth, J., et al. (2008) · Nature Medicine

RNA Interference and Gene Deliveryinterferon and immune responses

Cited by 387

Preclinical development of a subcutaneous ALAS1 RNAi therapeutic for treatment of hepatic porphyrias using circulating RNA quantification

Chan, A., Liebow, A., Yasuda, M., Gan, L., Racie, T., Maier, M., Kuchimanchi, S., Foster, D., Milstein, S., Charisse, K., et al. (2015) · Molecular Therapy — Nucleic Acids

Porphyrin Metabolism and DisordersRNA Interference and Gene Delivery

Cited by 128

Preclinical evaluation of RNAi as a treatment for transthyretin-mediated amyloidosis

Butler, J. S., Chan, A., Costelha, S., Fishman, S., Willoughby, J. L. S., Borland, T. D., Milstein, S., Foster, D. J., Gonçalves, P., Chen, Q., et al. (2016) · Amyloid

Amyloidosis: Diagnosis, Treatment, OutcomesAlzheimer's disease research and treatments

Cited by 113

An investigational RNAi therapeutic targeting factor XII (ALN-F12) for the treatment of hereditary Angioedema

Akinc, A., Liu, J., Qin, J., Castoreno, A., Schlegel, M., Maier, M., Fitzgerald, K., & Meyers, R. (2016) · Journal of Allergy and Clinical Immunology

Coagulation, Bradykinin, Polyphosphates, and AngioedemaHemophilia Treatment and Research

Cited by 5